Cullinan Therapeutics Statistics
Total Valuation
CGEM has a market cap or net worth of $1.13 billion. The enterprise value is $781.33 million.
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CGEM has 61.46 million shares outstanding. The number of shares has increased by 2.94% in one year.
| Current Share Class | 61.46M |
| Shares Outstanding | 61.46M |
| Shares Change (YoY) | +2.94% |
| Shares Change (QoQ) | +2.13% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 80.36% |
| Float | 44.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 176.79 |
| PB Ratio | 3.09 |
| P/TBV Ratio | 3.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.28 |
| Quick Ratio | 10.09 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -48.16% and return on invested capital (ROIC) is -957.81%.
| Return on Equity (ROE) | -48.16% |
| Return on Assets (ROA) | -30.57% |
| Return on Invested Capital (ROIC) | -957.81% |
| Return on Capital Employed (ROCE) | -65.34% |
| Weighted Average Cost of Capital (WACC) | 4.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.03M |
| Employee Count | 109 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +132.32% in the last 52 weeks. The beta is 0.01, so CGEM's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | +132.32% |
| 50-Day Moving Average | 14.75 |
| 200-Day Moving Average | 11.69 |
| Relative Strength Index (RSI) | 69.86 |
| Average Volume (20 Days) | 1,550,156 |
Short Selling Information
The latest short interest is 8.19 million, so 13.32% of the outstanding shares have been sold short.
| Short Interest | 8.19M |
| Short Previous Month | 7.97M |
| Short % of Shares Out | 13.32% |
| Short % of Float | 18.49% |
| Short Ratio (days to cover) | 6.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -240.35M |
| Pretax Income | -221.04M |
| Net Income | -221.04M |
| EBITDA | -240.04M |
| EBIT | -240.35M |
| Earnings Per Share (EPS) | -$3.72 |
Full Income StatementBalance Sheet
The company has $351.89 million in cash and $2.38 million in debt, giving a net cash position of $349.50 million or $5.69 per share.
| Cash & Cash Equivalents | 351.89M |
| Total Debt | 2.38M |
| Net Cash | 349.50M |
| Net Cash Per Share | $5.69 |
| Equity (Book Value) | 366.17M |
| Book Value Per Share | 5.96 |
| Working Capital | 326.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$178.64 million and capital expenditures -$49,000, giving a free cash flow of -$178.69 million.
| Operating Cash Flow | -178.64M |
| Capital Expenditures | -49,000 |
| Depreciation & Amortization | 314,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -178.69M |
| FCF Per Share | -$2.91 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |